Navigation Links
Omni Bio Pharmaceutical, Inc's. CEO Issues Letter to Shareholders
Date:3/31/2011

ni Bio's lead development programs is evaluating an FDA-approved, off-patent drug, AAT, for the treatment of Type 1 diabetes.  Novel discoveries made at UCD indicate that AAT has the potential to address a variety of indications in the areas of bacterial and viral disorders, biohazards, diabetes and transplant rejection.  For additional information, please visit www.omnibiopharma.com.

Forward-Looking StatementsSome of the statements made in this press release are forward-looking statements that reflect management's current views and expectations with respect to future events, including the expansion and commencement of clinical trials and the outcome and expenses of such trials. These forward-looking statements are not a guarantee of future events and are subject to a number of risks and uncertainties, many of which are outside our control, which could cause actual events to differ materially from those expressed or implied by the statements.  These risks and uncertainties are based on a number of factors, including but not limited to receipt of adequate funding to expand and commence clinical trials; receipt of applicable regulatory approvals for clinical trials, the risks related to the ownership and enforceability of our licensed intellectual property necessary to conduct the clinical trials and the business risks disclosed in our SEC filings, especially the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended March 31, 2010.  We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.Omni Bio Pharmaceutical, Inc.

Hayden IR  Edward C. Larkin, Chief Operating Officer

Brett Maas, Managing Partner(720) 488-4708

(646) 536-7331 Email: brett@haydenir.com'/>"/>

SOURCE Omni Bio Pharmaceutical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
2. Tianyin Pharmaceutical, Co. Announces Cash Dividend to Common Shareholders - Record Date October 30, 2009
3. National Pharmaceutical Council Welcomes New Member, Otsuka America Pharmaceutical, Inc.
4. Shengtai Pharmaceutical, Inc Announces Appointment of New Chief Financial Officer
5. Shengtai Pharmaceutical, Inc. Reports Financial Results for the Third Quarter and the First Nine Months of Fiscal Year 2010
6. Ortho-McNeil Pharmaceutical, LLC Pleads Guilty to Illegal Promotion of Topamax and is Sentenced to Criminal Fine of $6.14 Million
7. WellSpring Pharmaceutical, American Gastroenterological Association, and Steven Bramson of Humanscale Partner With MediaPlanet to Publish One of the Largest Digestive Wellness Campaigns in U.S. History to Overcome Upset Stomach, Nausea, IBS, and Deb
8. Masters Pharmaceutical, Inc. Appoints Wayne A. Corona to President and Chief Operating Officer
9. The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy
10. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
11. European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... Mass. and TORONTO , ... ) (OTCBB: GNBT) today announced three presentations demonstrating the ... by its wholly-owned subsidiary, Antigen Express, Inc. ( www.antigenexpress.com ... meeting of the American Society of Clinical Oncology (ASCO) ... from May 31 through June 4, 2013. ...
(Date:5/22/2013)...  Grifols, ein globales Unternehmen der Gesundheitsbranche ... , Spanien, präsentierte die Ergebnisse einer Studie, ... PROLASTIN©-C (Alpha1-Proteinasehemmer [human]) den Spiegel des Alpha1-Proteins ... Niveau anhebt, das innerhalb des für gesunde ... eine lebensbedrohliche, genetische Erkrankung, bei der der ...
(Date:5/22/2013)... and TORONTO , May 22, 2013 ... that John Mon , Chief Operating Officer, ... on Thursday, May 30, 2013 in New York ... The Company,s presentation is scheduled to begin at 4:00 ... To access the webcast, go to:   http://wsw.com/webcast/marcum/mfs.v/   ...
Breaking Medicine Technology:Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 2Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 3Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 4Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 2Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 3Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 4Medifocus, Inc. to Present At The Second Annual Marcum LLP MicroCap Conference 2Medifocus, Inc. to Present At The Second Annual Marcum LLP MicroCap Conference 3
... Trubion,s Proprietary ... Product Candidate, SBI-087 for RA Expands Trubion,s Family of Customized, Differentiated ... Product Candidates, ... has initiated a Phase 1/2,clinical trial of TRU-016, the company,s lead proprietary Small Modular,ImmunoPharmaceutical ...
... Encouraging Response in CF Patients - Results Validate ... March 27 The Cystic Fibrosis Foundation,announced today that ... defect in CF, showed promising results in an ongoing ... mutation of CF. The drug is,being developed by Vertex ...
Cached Medicine Technology:Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update 2Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update 3Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update 4Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update 5Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF 2Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF 3
(Date:5/22/2013)... these findings in the current online edition of ... study could open up new possibilities of early ... tackle diseases before the patient,s nervous system is ... of genetic diseases of the cerebellum and other ... limited control of their muscles. They also suffer ...
(Date:5/22/2013)... baby to finish the last ounce in their bottle might ... soon burn off, a bad habit remains. , Brigham Young ... clinical obesity at 24 months of age strongly traces back ... two, it puts you on a trajectory where you are ... as an adult," said Forste. "That,s a big concern." , ...
(Date:5/22/2013)... May 22, 2013 College and ... access to Adapt Courseware’s new Introduction to ... adaptive framework that responds based on each student’s ... the provider of comprehensive adaptive online curriculum resources ... to develop introductory level general education offerings, enabling ...
(Date:5/22/2013)... 22, 2013 Officials with Alliance Commercial ... cicada services are now in full effect due to ... cicada cycle emerges. , “The cicada emerges in ... they will emerge, so we’re now offering services to ... protected during the invasion,” said R. Brett Madden, Esq., ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 According to ... an autoimmune disorder effecting up to 3 million people ... damage to the small intestine and mal-absorption of nutrients(2). ... as diarrhea, constipation, weight loss and vitamin deficiency, people ... While there are many gluten-free foods that celiac sufferers ...
Breaking Medicine News(10 mins):Health News:A pan-European study: Signs of motor disorders can appear years before disease manifestation 2Health News:A pan-European study: Signs of motor disorders can appear years before disease manifestation 3Health News:Overeating learned in infancy, study suggests 2Health News:Adapt Courseware Releases Introduction to Sociology for Colleges and Universities Nationwide 2Health News:Adapt Courseware Releases Introduction to Sociology for Colleges and Universities Nationwide 3Health News:Alliance Commercial Pest Control, Inc. Now Offering Cicada Protection Services 2Health News:During Celiac Awareness Month, Nutrition Expert Keri Glassman Encourages People with Celiac Disease to Find a Fiber Alternative like Konsyl Original Formula 2Health News:During Celiac Awareness Month, Nutrition Expert Keri Glassman Encourages People with Celiac Disease to Find a Fiber Alternative like Konsyl Original Formula 3
... troubles ,the day after, and protect liver from damage, experts ... a hangover, drink lots of water, get plenty of rest ... study shows that the amino acids and minerals in asparagus ... toxins in alcohol. , Researchers at the Institute of Medical ...
... a technique widely used in studying the human brain. ... signals are generated at brain cell level. This information ... from the Academy of Finland,s Neuroscience Research Programme (NEURO) ... play a key role in the generation of fMRI ...
... and the University of Pittsburgh Medical Center will be ... conjunction with the G20 Pittsburgh Summit Sept. 24-25. These ... how and why the "eds and meds" sector of ... region,s success. The Eds-Meds program will begin at ...
... , RUTHERFORD, N.J., Aug. 28 As ... to soar, and sales and profits are being diverted ... commitment to keep their Vectra(R) products, and the health ... professionals. Through their Bloodhound(R) Technology, a unique track-and-trace barcode ...
... MUMBAI, India, Aug. 28 Sun Pharmaceutical Industries Ltd. (Reuters: ... announced that on August 27, 2009, Sun filed a new ... Antitrust Division of the U.S. Department of Justice to restart ... Tender Offer by Alkaloida Chemical Company Exclusive Group Ltd. (Alkaloida), ...
... someday aid in understanding ADD and more , FRIDAY, Aug. ... in a crowd, it appears that your "mind,s eye" acts ... you until you find the right person. , Researchers from ... monkeys as they searched for a specific tilted, colored bar ...
Cached Medicine News:Health News:Asparagus May Ease Hangover 2Health News:New research findings pave the way to more accurate interpretation of brain imaging data 2Health News:Summit VetPharm Helps Veterinarians Protect Against Product Diversion, Counterfeiting and Shrinkage Using Vectra(R) Bloodhound(R) Technology 2Health News:Summit VetPharm Helps Veterinarians Protect Against Product Diversion, Counterfeiting and Shrinkage Using Vectra(R) Bloodhound(R) Technology 3Health News:Sun Pharmaceutical Files HSR Application for Taro Tender Offer 2Health News:Sun Pharmaceutical Files HSR Application for Taro Tender Offer 3Health News:Brain May Use Its 'Mind's Eye' to Control Chaos 2
Malaria Pf. Assay Range...
An immunochromatographic test for detection of 4 species of Plasmodium antigen ( P. falciparum , P. vivax , P. malariae , P. ovale ) in whole blood....
192 Test HRP-II Enzyme Immunoassay for the presence of Plasmodium falciparum infection....
Malaria device / strip (3 line, PAN-pLDH, P.f.-HRP2)...
Medicine Products: